Skip to main
PASG

PASSAGE BIO (PASG) Stock Forecast & Price Target

PASSAGE BIO (PASG) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Passage Bio Inc is focused on developing innovative therapies for rare, monogenic CNS disorders, with products addressing conditions such as GM1 Gangliosidosis and Frontotemporal dementia. Recent interim data suggest PBFT02 demonstrates sustained efficacy, marked by a mean cerebrospinal fluid (CSF) progranulin increase and an overall positive trajectory in biomarker improvements, which may facilitate regulatory approval and reduce trial duration. Moreover, the strategic design of its registrational trials, which may pursue approval based on biomarkers alone, positions Passage Bio favorably to capitalize on potential advancements in genetic medicine.

Bears say

The financial outlook for Passage Bio Inc is negatively impacted by various clinical and regulatory risks associated with its gene therapy programs. The potential for delays in clinical timelines and the emergence of unforeseen safety signals raise significant concerns regarding market sentiment and may lead to downward revisions in financial estimates. Moreover, insufficient manufacturing capacity poses an additional risk that could materially constrain the company's forecasts and hinder its ability to deliver on its developmental targets.

PASSAGE BIO (PASG) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PASSAGE BIO (PASG) Forecast

Analysts have given PASSAGE BIO (PASG) a Strong Buy based on their latest research and market trends.

According to 4 analysts, PASSAGE BIO (PASG) has a Strong Buy consensus rating as of Dec 31, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PASSAGE BIO (PASG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.